Placebo + ADUCANUMAB for alzheimer disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 5 May 2015: Trial registered, NCT02434718
  2. 24 Jun 2015: Trial started, NCT02434718

The trials

NCT02434718: Single and Multiple Ascending Dose Study of Aducanumab (BIIB037) in Japanese Participants With Alzheimer's Disease

State
Completed
Phase
Phase 1
People
21 taking part
Started
24 Jun 2015
Primary completion
9 Dec 2016
Arms
Cohort 1, Cohort 2, Cohort 3, Cohort 4
Results
None posted
  1. 5 May 2015: Trial registered
  2. 24 Jun 2015: Trial started
  3. 9 Dec 2016: Trial completed

NCT02477800: 221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

State
Stopped early
Phase
Phase 3
People
1,653 taking part
Started
13 Aug 2015
Primary completion
8 Aug 2019
Arms
Low Dose, High Dose
Results
Posted on the registry
  1. 23 Jun 2015: Trial registered
  2. 13 Aug 2015: Trial started
  3. 8 Aug 2019: Trial terminated
  4. 2 Sep 2021: Trial results posted

NCT02484547: 221AD302 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

State
Stopped early
Phase
Phase 3
People
1,643 taking part
Started
15 Sep 2015
Primary completion
5 Aug 2019
Arms
Low Dose, High Dose
Results
Posted on the registry
  1. 29 Jun 2015: Trial registered
  2. 15 Sep 2015: Trial started
  3. 5 Aug 2019: Trial terminated
  4. 2 Sep 2021: Trial results posted

NCT03639987: A Study of Aducanumab in Participants With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease Dementia to Evaluate the Safety of Continued Dosing in Participants With Asymptomatic Amyloid-Related Imaging Abnormalities

State
Stopped early
Phase
Phase 2
People
52 taking part
Started
20 Dec 2018
Primary completion
30 Jul 2019
Arms
Group 1
Results
Posted on the registry
  1. 21 Aug 2018: Trial registered
  2. 20 Dec 2018: Trial started
  3. 30 Jul 2019: Trial terminated
  4. 16 Sep 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.